Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: immune cell therapies - Creative Medical Technology Holdings

Drug Profile

Research programme: immune cell therapies - Creative Medical Technology Holdings

Alternative Names: adoptive immunotherapy; CELZ-101; IMMCELZ; reprogrammed immune cells; reprogrammed T cells

Latest Information Update: 18 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Creative Medical Technology Holdings
  • Class Cell therapies
  • Mechanism of Action Cell replacements; Hepatocyte growth factor modulators; Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Type 1 diabetes mellitus
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Heart failure; Liver failure; Parkinson's disease; Renal failure; Rheumatoid arthritis; Stroke; Type 1 diabetes mellitus

Most Recent Events

  • 06 Mar 2024 Research programme: immune cell therapies receives Orphan Drug status for Type 1 diabetes mellitus in USA
  • 09 Jun 2021 Creative Medical Technology Holdings plans to file IND application with the US FDA for Type 1 diabetes mellitus
  • 09 Jun 2021 Pharmacodynamics data from preclinical studies in Type 1 diabetes mellitus released by Creative Medical Technology Holdings
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top